Acelyrin (SLRN) Adopts Limited-Duration Stockholder Rights Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- S&P 500 and Nasdaq slip as chip rout extends; Netflix slides
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
March 13, 2025 7:00 AM EDTLOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners continued rapid accumulation of 8.8% of ACELYRINS outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan (Rights Plan).
The ACELYRIN Board and management team continue to engage with stockholders and are focused on maximizing stockholder value.
Pursuant to the Rights Plan, the Company is... More
